

**Question for written answer E-003512/2018**  
**to the Commission**  
Rule 130  
**Mireille D'Ornano (EFDD)**

Subject: The risk associated with the use of the neonicotinoids: clothianidin, imidacloprid and thiamethoxam

At a hearing of the European Parliament's PEST Committee on the authorisation of the neonicotinoids clothianidin, imidacloprid and thiamethoxam, an industry representative said: 'We disagree with the Commission's conclusions, not with the EFSA's' and went on to say that 'the EFSA has evaluated more than 500 scenarios on bees [...] and estimates that in 4% of these scenarios there is a high risk that cannot be excluded, [...] therefore for the remaining 96% there are safe uses for neonicotinoids'

How can the Commission justify its decision of April 2018 to advocate the prohibition of the 3 neonicotinoids concerned, if, in 96% of the scenarios envisaged, there apparently exist safe uses for these substances?